United Therapeutics (UTHR) Tops Q1 EPS by 19c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
JMP Securities Downgrades SteadyMed (STDY) to Market Perform Following Acquisition
May 1, 2018 3:25 AM EDTJMP Securities downgraded SteadyMed (NASDAQ: STDY) from Market Outperform to Market Perform.
Analyst Donald Ellis steps to the sideline following the recent acquisition by United Therapeutics (NASDAQ: UTHR). The analyst is not expecting a competing offer to... More
Pre-Open Movers 04/30: (STDY) (ANDV) (FDC) Higher; (CTB) (S) (ARNC) Lower (more...)
April 30, 2018 9:27 AM EDTToday's Pre-Open Movers
SteadyMed Ltd. (NASDAQ: STDY) 81.1% HIGHER; United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million.
Pluristem Therapeutics Inc. (Nasdaq:... More
